[go: up one dir, main page]

WO2000063245A3 - Vaccin - Google Patents

Vaccin Download PDF

Info

Publication number
WO2000063245A3
WO2000063245A3 PCT/GB2000/001558 GB0001558W WO0063245A3 WO 2000063245 A3 WO2000063245 A3 WO 2000063245A3 GB 0001558 W GB0001558 W GB 0001558W WO 0063245 A3 WO0063245 A3 WO 0063245A3
Authority
WO
WIPO (PCT)
Prior art keywords
variant
msp
plasmodium
surface protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/001558
Other languages
English (en)
Other versions
WO2000063245A2 (fr
WO2000063245A9 (fr
Inventor
Anthony Holder
Berry Birdsall
James Feeney
William Morgan
Shabih Syed
Chairat Uthaipibull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9909072.2A external-priority patent/GB9909072D0/en
Priority to AU41330/00A priority Critical patent/AU779662B2/en
Priority to BR0009823-0A priority patent/BR0009823A/pt
Priority to MXPA01010701A priority patent/MXPA01010701A/es
Priority to HK02104693.0A priority patent/HK1043135A1/zh
Priority to JP2000612331A priority patent/JP2002543774A/ja
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to EP00920918A priority patent/EP1180120A2/fr
Publication of WO2000063245A2 publication Critical patent/WO2000063245A2/fr
Publication of WO2000063245A3 publication Critical patent/WO2000063245A3/fr
Priority to US09/978,756 priority patent/US7078043B2/en
Anticipated expiration legal-status Critical
Publication of WO2000063245A9 publication Critical patent/WO2000063245A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une variante d'origine non naturelle d'un fragment C-terminal d'une protéine de surface de mérozoïte 1 (MSP-1) de Plasmodium. Cette variante présente (i) une affinité réduite, si l'on compare avec une MCP-119 de Plasmodium d'origine naturelle, pour au moins un premier anticorps pouvant bloquer la liaison d'un second anticorps inhibant le clivage protéolytique d'une MSP-142 de Plasmodium, et (ii) sensiblement la même affinité pour au moins un troisième anticorps, si l'on compare avec ladite MCP-119 de Plasmodium d'origine naturelle, ce troisième anticorps inhibant le clivage protéolytique de la MSP-142 de Plasmodium. Cette variante s'utilise dans un vaccin contre la malaria.
PCT/GB2000/001558 1999-04-20 2000-04-20 Vaccin Ceased WO2000063245A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP00920918A EP1180120A2 (fr) 1999-04-20 2000-04-20 Variante de la proteine de surface du merozoite (msp-1) de plasmodium et vaccin la comprenant
BR0009823-0A BR0009823A (pt) 1999-04-20 2000-04-20 Variante da proteìna de superfìcie de plasmodium merozoito (msp-1) e vacina compreendendo a variante
MXPA01010701A MXPA01010701A (es) 1999-04-20 2000-04-20 Vacuna.
HK02104693.0A HK1043135A1 (zh) 1999-04-20 2000-04-20 原蟲分裂殖子表面蛋白(msp-1)的異變物及含該異變物的疫苗
JP2000612331A JP2002543774A (ja) 1999-04-20 2000-04-20 ワクチン
AU41330/00A AU779662B2 (en) 1999-04-20 2000-04-20 Vaccine
US09/978,756 US7078043B2 (en) 1999-04-20 2001-10-16 Malaria vaccine

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9909072.2 1999-04-20
GBGB9909072.2A GB9909072D0 (en) 1999-04-20 1999-04-20 Vaccine
US31181799A 1999-05-13 1999-05-13
US09/311,817 1999-05-13
CA2,271,451 1999-05-25
CA002271451A CA2271451A1 (fr) 1999-04-20 1999-05-25 Variant d'un fragment c-terminal de la msp-1 de plasmodium falciparum

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US31181799A Continuation-In-Part 1999-04-20 1999-05-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/978,756 Continuation US7078043B2 (en) 1999-04-20 2001-10-16 Malaria vaccine

Publications (3)

Publication Number Publication Date
WO2000063245A2 WO2000063245A2 (fr) 2000-10-26
WO2000063245A3 true WO2000063245A3 (fr) 2001-05-03
WO2000063245A9 WO2000063245A9 (fr) 2002-08-29

Family

ID=27170966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001558 Ceased WO2000063245A2 (fr) 1999-04-20 2000-04-20 Vaccin

Country Status (7)

Country Link
EP (1) EP1180120A2 (fr)
JP (1) JP2002543774A (fr)
CN (1) CN1372568A (fr)
AU (1) AU779662B2 (fr)
BR (1) BR0009823A (fr)
MX (1) MXPA01010701A (fr)
WO (1) WO2000063245A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855322B2 (en) 2001-01-26 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Isolation and purification of P. falciparum merozoite protein-142 vaccine
US7595191B2 (en) 2001-01-26 2009-09-29 The United States Of America As Represented By The Secretary Of The Army Isolation and purification of P. falciparum merozoite protein-142 vaccine
CN1176945C (zh) 2001-02-01 2004-11-24 中国人民解放军第二军医大学 疟原虫融合抗原及其制法和用途
US7256281B2 (en) 2002-04-01 2007-08-14 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
WO2015056244A1 (fr) * 2013-10-18 2015-04-23 Universidade Federal De Minas Gerais - Ufmg Trousse et méthode immunodiagnostique pour la détection de l'anémie liée à la malaria vivax, peptides synthétiques et utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030158A2 (fr) * 1996-02-14 1997-08-21 Institut Pasteur Proteine recombinante contenant un fragment c-terminal de msp-1 de plasmodium

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030158A2 (fr) * 1996-02-14 1997-08-21 Institut Pasteur Proteine recombinante contenant un fragment c-terminal de msp-1 de plasmodium

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
AUFIERO B M ET AL: "Epitope mapping of mAbs that inhibit or block secondary processing of MSP142.", AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, vol. 61, no. 3 SUPPL., 1999, 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene;Washington, D.C., USA; November 28-December 2, 1999, pages 345 - 346, XP000957837, ISSN: 0002-9637 *
BLACKMAN MICHAEL J ET AL: "Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 180, no. 1, 1994, pages 389 - 393, XP000957584, ISSN: 0022-1007 *
DATABASE GENEMBL 24 March 1998 (1998-03-24), KANEKO, O.: "Plasmodium falciparum gene for merozoite surface protein 1, partial cds", XP002154053 *
DATABASE GENEMBL 7 September 1993 (1993-09-07), JONGWUTIVES, S.: "P.falciparum DNA for the precursor to the major merozoite surface proteins, C-terminal", XP002154052 *
JONGWUTIWES ET AL.: "Sequence conservation in the C-terminal part of the precursor to the major merozoite surface proteins (MSP1) of Plasmodium falciparum from field isolates", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 59, 1 January 1993 (1993-01-01), pages 95 - 100, XP000603762 *
KANEKO ET AL.: "Plasmodium falciparum: Allelic variation in the merozoite surface protein 1 gene in wild isolates from southern Vietnam", EXPERIMENTAL PARASITOLOGY, vol. 86, no. 1, 1997, pages 45 - 57, XP000972338 *
KASLOW DAVID C ET AL: "Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1-19) variants secreted from Saccharomyces cerevisiae.", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 63, no. 2, 1994, pages 283 - 289, XP000603953, ISSN: 0166-6851 *
KOCKEN CLEMENS H M ET AL: "High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: Strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2.", INFECTION AND IMMUNITY, vol. 67, no. 1, January 1999 (1999-01-01), pages 43 - 49, XP002153976, ISSN: 0019-9567 *
LALITHA P V ET AL: "Plasmodium falciparum: Variations in the C-terminal cysteine-rich region of the merozoite surface protein-1 in field samples among Indian isolates.", EXPERIMENTAL PARASITOLOGY, vol. 92, no. 1, May 1999 (1999-05-01), pages 12 - 18, XP000957557, ISSN: 0014-4894 *
LONGACRE SHIRLEY ET AL: "Plasmodium vivax merozoite surface protein 1 C-terminal recombinant proteins in baculovirus.", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 64, no. 2, 1994, pages 191 - 205, XP000603954, ISSN: 0166-6851 *
MORGAN WILLIAM D ET AL: "Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1.", JOURNAL OF MOLECULAR BIOLOGY, vol. 289, no. 1, 28 May 1999 (1999-05-28), pages 113 - 122, XP000957556, ISSN: 0022-2836 *
PAN WEIQING ET AL: "Vaccine candidate MSP-1 from Plasmodium falciparum: A redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells.", NUCLEIC ACIDS RESEARCH, vol. 27, no. 4, 15 February 1999 (1999-02-15), pages 1094 - 1103, XP000953100, ISSN: 0305-1048 *
PATINO JOSE A GUEVARA ET AL: "Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 10, 17 November 1997 (1997-11-17), pages 1689 - 1699, XP000957550, ISSN: 0022-1007 *
PERERA K L R LAKSHMAN ET AL: "Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria.", INFECTION AND IMMUNITY, vol. 66, no. 4, April 1998 (1998-04-01), pages 1500 - 1506, XP002153977, ISSN: 0019-9567 *
VEDVICK T S: "GENE EXPRESSION IN YEAST: PICHIA PASTORIS", CURRENT OPINION IN BIOTECHNOLOGY,GB,LONDON, 1991, pages 742 - 745, XP000915577, ISSN: 0958-1669 *

Also Published As

Publication number Publication date
AU4133000A (en) 2000-11-02
JP2002543774A (ja) 2002-12-24
CN1372568A (zh) 2002-10-02
WO2000063245A2 (fr) 2000-10-26
MXPA01010701A (es) 2003-08-20
AU779662B2 (en) 2005-02-03
EP1180120A2 (fr) 2002-02-20
WO2000063245A9 (fr) 2002-08-29
BR0009823A (pt) 2002-04-09

Similar Documents

Publication Publication Date Title
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
AU2001263343A1 (en) Ballast block deck system and pedestal assembly therefor
AU1756799A (en) Epoxidation catalyst, its use and epoxidation method in the presence of said catalyst
AU2849701A (en) Components and catalysts for the polymerization of olefins
WO2003016489A8 (fr) Proteine, oligonucleotide anti-sens et anticorps de leptine porcine
AU4556597A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AU2002230953A1 (en) Recombinant phytases and uses thereof
WO2000063245A3 (fr) Vaccin
AU7471098A (en) Recombinant influenza viruses expressing tumor-associated antigens as antitum or agents
AU2001269934A1 (en) Polypeptides having peroxidase activity and nucleic acids encoding same
AU2002233424A1 (en) Peptides having affinity for the GP120 viral protein and use thereof
AU1884297A (en) Recombinant protein containing a c-terminal fragment of plasmodium msp-1
AU3273901A (en) Quantification of cellular injury using expression of a fluorescent protein under the control of the GADD153 promoter
AU2002232803A1 (en) Expression system for recombinant proteins
AU3437597A (en) Recombinant ribosomal inhibitor protein (rip) and use as immunoconjugate
AU2001259209A1 (en) Human abc1 promoter and assays based thereon
AU2002341828A1 (en) Enhanced proteins and methods for their use
WO2002053587A3 (fr) Polypeptide induisant des anticorps neutralisant le vih
AUPQ599500A0 (en) Novel peptides, modulatory agents therefor and methods of using them
AU2002213954A1 (en) Method for the selective modification of peptides and proteins
AU2002213259A1 (en) Egf motif protein, egfl6 materials and methods
AU2002216493A1 (en) Catalysts and the hydroformylation of olefins
AU2002321852A1 (en) Recombinant polypeptide for immunocastration and vaccine comprising the same
AU2002364507A8 (en) Mammary-associated serum amyloid a3 promoter sequences and uses for same
AU2001274563A1 (en) Novel polypeptide and its dna

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00809259.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00905/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 09978756

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2000 612331

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010701

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000920918

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000920918

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 106 AND 107, CLAIMS, REPLACED BY NEW PAGES 106 AND 107; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY